DK1244805T3 - Virale kerneprotein-kationiske lipid-nukleinsyre-frigivelseskomplekser - Google Patents
Virale kerneprotein-kationiske lipid-nukleinsyre-frigivelseskomplekserInfo
- Publication number
- DK1244805T3 DK1244805T3 DK00981481T DK00981481T DK1244805T3 DK 1244805 T3 DK1244805 T3 DK 1244805T3 DK 00981481 T DK00981481 T DK 00981481T DK 00981481 T DK00981481 T DK 00981481T DK 1244805 T3 DK1244805 T3 DK 1244805T3
- Authority
- DK
- Denmark
- Prior art keywords
- nucleic acid
- cationic lipid
- noi
- nuclear protein
- acid release
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Dispersion Chemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9930533.6A GB9930533D0 (en) | 1999-12-23 | 1999-12-23 | Nucleic acid delivery |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1244805T3 true DK1244805T3 (da) | 2006-06-26 |
Family
ID=10866964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00981481T DK1244805T3 (da) | 1999-12-23 | 2000-12-12 | Virale kerneprotein-kationiske lipid-nukleinsyre-frigivelseskomplekser |
Country Status (16)
Country | Link |
---|---|
US (2) | US20030153081A1 (pt) |
EP (2) | EP1244805B1 (pt) |
JP (1) | JP2003518388A (pt) |
CN (1) | CN100354426C (pt) |
AT (1) | ATE318322T1 (pt) |
AU (1) | AU781356B2 (pt) |
CA (1) | CA2395454A1 (pt) |
CZ (1) | CZ298353B6 (pt) |
DE (1) | DE60026164T2 (pt) |
DK (1) | DK1244805T3 (pt) |
ES (1) | ES2258986T3 (pt) |
GB (1) | GB9930533D0 (pt) |
PT (1) | PT1244805E (pt) |
RU (1) | RU2267536C2 (pt) |
UA (1) | UA77393C2 (pt) |
WO (1) | WO2001048233A1 (pt) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0118517D0 (en) * | 2001-07-30 | 2001-09-19 | Mitsubishi Tokyo Pharm Inc | Compound |
FR2829136B1 (fr) * | 2001-08-29 | 2006-11-17 | Aventis Pharma Sa | Derives lipidiques d'aminoglycosides |
AU2002334051B2 (en) * | 2001-08-29 | 2008-05-15 | Aventis Pharma S.A. | Aminoglycoside lipid derivatives for transfection |
WO2004110980A1 (en) | 2003-06-18 | 2004-12-23 | Biolab Ltd. | Sphingolipids' polyalkylamines conjugates |
US7906122B2 (en) | 2003-06-18 | 2011-03-15 | Yissum Research Development Company Of The Hebrew University Of Jersusalem | Sphingoid polyalkylamine conjugates for Hepatitis B virus vaccination |
GB0418172D0 (en) * | 2004-08-13 | 2004-09-15 | Ic Vec Ltd | Vector |
US20090155853A1 (en) * | 2005-11-18 | 2009-06-18 | Gary Nabel | Non-viral gene delivery complex |
WO2008052766A2 (en) * | 2006-11-03 | 2008-05-08 | Medigene Ag | Cationic colloidal carriers for delivery of active agents to the blood-brain barrier in the course of neuroinflammatory diseases |
WO2008056623A1 (fr) * | 2006-11-09 | 2008-05-15 | Daiichi Sankyo Company, Limited | Composition pour l'introduction d'acide nucléique |
EP2105145A1 (en) * | 2008-03-27 | 2009-09-30 | ETH Zürich | Method for muscle-specific delivery lipid-conjugated oligonucleotides |
WO2010042751A2 (en) * | 2008-10-08 | 2010-04-15 | Chimeros Inc. | Chimeric therapeutics, compositions, and methods for using same |
EP4241767A3 (en) | 2008-11-10 | 2023-11-01 | Arbutus Biopharma Corporation | Novel lipids and compositions for the delivery of therapeutics |
WO2010120874A2 (en) * | 2009-04-14 | 2010-10-21 | Chimeros, Inc. | Chimeric therapeutics, compositions, and methods for using same |
US8865188B2 (en) | 2011-09-09 | 2014-10-21 | Biomed Realty, L.P. | Methods and compositions for controlling assembly of viral proteins |
ES2921724T1 (es) | 2011-12-07 | 2022-08-31 | Alnylam Pharmaceuticals Inc | Lípidos biodegradables para la administración de agentes activos |
CA2953341C (en) | 2014-06-25 | 2023-01-24 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
AU2016285852B2 (en) | 2015-06-29 | 2020-12-17 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
US10829787B2 (en) * | 2015-10-14 | 2020-11-10 | Life Technologies Corporation | Ribonucleoprotein transfection agents |
EP3368507B1 (en) | 2015-10-28 | 2022-12-07 | Acuitas Therapeutics Inc. | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
EP3468608A1 (en) * | 2016-06-09 | 2019-04-17 | CureVac AG | Hybrid carriers for nucleic acid cargo |
RU2751001C2 (ru) | 2016-06-09 | 2021-07-07 | Кьюрвак Аг | Гибридные носители для доставки нуклеиновых кислот |
US11357856B2 (en) | 2017-04-13 | 2022-06-14 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
US11660332B2 (en) | 2017-04-27 | 2023-05-30 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus |
EP3615510B1 (en) | 2017-04-28 | 2024-03-27 | Acuitas Therapeutics, Inc. | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
US11639329B2 (en) | 2017-08-16 | 2023-05-02 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
US11542225B2 (en) | 2017-08-17 | 2023-01-03 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
US11524932B2 (en) | 2017-08-17 | 2022-12-13 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
BR112021013654A2 (pt) | 2019-01-11 | 2021-09-14 | Acuitas Therapeutics, Inc. | Lipídeos para liberação de nanopartículas lipídicas de agentes ativos |
JP2021016370A (ja) * | 2019-07-23 | 2021-02-15 | 株式会社東芝 | 核酸導入キャリア、核酸導入キャリアセット、核酸導入組成物及び核酸導入方法 |
CN110408656A (zh) * | 2019-07-29 | 2019-11-05 | 成都朴名生物科技有限公司 | 脂多聚物体及其制备方法、采用脂多聚物体将基因编辑质粒导入真核细胞的方法 |
CN110452303B (zh) * | 2019-08-08 | 2022-03-04 | 中国科学院武汉病毒研究所 | 共价连接核酸和肽或蛋白的方法及应用 |
CN111394313A (zh) * | 2020-04-01 | 2020-07-10 | 河南科技学院 | 一种人造细胞及其制备方法 |
WO2022016070A1 (en) | 2020-07-16 | 2022-01-20 | Acuitas Therapeutics, Inc. | Cationic lipids for use in lipid nanoparticles |
CN114656422B (zh) * | 2022-04-22 | 2023-05-23 | 重庆理工大学 | 一种新型氮杂冠醚化合物及其阳离子脂质体、制备方法与应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH574396A5 (pt) * | 1969-12-29 | 1976-04-15 | Richter Gedeon Vegyeszet | |
US4189431A (en) * | 1975-08-04 | 1980-02-19 | The Board of Trustees of Leland Stanford Junior University | Alkinyl terminating groups in biogenetic-like cyclizations to steroids |
US5283185A (en) * | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
IL112372A (en) * | 1994-02-07 | 2001-08-26 | Res Dev Foundation | Non-viral vector for the delivery of genetic information to cells |
US5510510A (en) * | 1994-05-10 | 1996-04-23 | Bristol-Meyers Squibb Company | Inhibitors of farnesyl protein transferase |
US6051429A (en) * | 1995-06-07 | 2000-04-18 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
WO1996040961A1 (en) * | 1995-06-07 | 1996-12-19 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
CN1181422A (zh) * | 1996-10-31 | 1998-05-13 | 上海市肿瘤研究所 | 与生长因子受体结合的多肽所构建的基因转移载体 |
ATE229538T1 (de) * | 1999-03-09 | 2002-12-15 | Akzo Nobel Nv | 22r-hydroxycholesta-8,14-diene derivate zur hemmung der meiose |
-
1999
- 1999-12-23 GB GBGB9930533.6A patent/GB9930533D0/en not_active Ceased
-
2000
- 2000-12-12 DK DK00981481T patent/DK1244805T3/da active
- 2000-12-12 UA UA2002076053A patent/UA77393C2/uk unknown
- 2000-12-12 AU AU18716/01A patent/AU781356B2/en not_active Ceased
- 2000-12-12 CZ CZ20022193A patent/CZ298353B6/cs not_active IP Right Cessation
- 2000-12-12 WO PCT/GB2000/004767 patent/WO2001048233A1/en active IP Right Grant
- 2000-12-12 DE DE60026164T patent/DE60026164T2/de not_active Expired - Fee Related
- 2000-12-12 CN CNB008191468A patent/CN100354426C/zh not_active Expired - Fee Related
- 2000-12-12 JP JP2001548745A patent/JP2003518388A/ja active Pending
- 2000-12-12 RU RU2002119560/13A patent/RU2267536C2/ru not_active IP Right Cessation
- 2000-12-12 US US10/168,909 patent/US20030153081A1/en not_active Abandoned
- 2000-12-12 ES ES00981481T patent/ES2258986T3/es not_active Expired - Lifetime
- 2000-12-12 EP EP00981481A patent/EP1244805B1/en not_active Expired - Lifetime
- 2000-12-12 CA CA002395454A patent/CA2395454A1/en not_active Abandoned
- 2000-12-12 AT AT00981481T patent/ATE318322T1/de not_active IP Right Cessation
- 2000-12-12 PT PT00981481T patent/PT1244805E/pt unknown
- 2000-12-12 EP EP04077588A patent/EP1566445A3/en not_active Withdrawn
-
2008
- 2008-10-30 US US12/261,999 patent/US20090209037A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2258986T3 (es) | 2006-09-16 |
CN100354426C (zh) | 2007-12-12 |
EP1244805A1 (en) | 2002-10-02 |
RU2267536C2 (ru) | 2006-01-10 |
AU1871601A (en) | 2001-07-09 |
CZ298353B6 (cs) | 2007-09-05 |
CZ20022193A3 (cs) | 2003-02-12 |
EP1566445A3 (en) | 2005-08-31 |
AU781356B2 (en) | 2005-05-19 |
DE60026164T2 (de) | 2006-11-16 |
US20090209037A1 (en) | 2009-08-20 |
CA2395454A1 (en) | 2001-07-05 |
WO2001048233A1 (en) | 2001-07-05 |
DE60026164D1 (de) | 2006-04-27 |
US20030153081A1 (en) | 2003-08-14 |
PT1244805E (pt) | 2006-07-31 |
ATE318322T1 (de) | 2006-03-15 |
RU2002119560A (ru) | 2004-03-27 |
UA77393C2 (en) | 2006-12-15 |
JP2003518388A (ja) | 2003-06-10 |
EP1244805B1 (en) | 2006-02-22 |
CN1434870A (zh) | 2003-08-06 |
GB9930533D0 (en) | 2000-02-16 |
EP1566445A2 (en) | 2005-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1244805T3 (da) | Virale kerneprotein-kationiske lipid-nukleinsyre-frigivelseskomplekser | |
DE69834022D1 (de) | Fusionproteine für intra- und interzelluläre transport und deren verwendungen | |
FI931109A0 (fi) | Peptider och nukleinsyrasekvenser, som haenfoer sig till epstein-barr-virus | |
CA2305013A1 (en) | Fusion proteins comprising hiv-1 tat and/or nef proteins | |
AU3192889A (en) | T cell activation markers | |
NZ244291A (en) | Virus-antibody conjugates for introducing nucleic acids into higher eukaryotic cells | |
AU571128B2 (en) | Expression of immunologically reactive aids viral protein | |
WO1999067382A3 (en) | Angiopoietin-like growth factor sequences | |
WO1997031934A3 (de) | Neue metabolisierbare lipopolyamine, deren darstellung und anwendung | |
CA2379346A1 (en) | Conjugate for mediating cell-specific, compartment-specific or membrane-specific transport of active substances | |
CY1107431T1 (el) | Σωματιδια για γoνιδιακη θεραπεια | |
WO1997040147A8 (en) | Antigenically reactive regions of the hepatitis a virus polyprotein | |
AU630861B2 (en) | Recombinant hiv-2 polypeptides | |
DK0442372T3 (da) | Forbedrede mærkede haptener, fremgangsmåde til deres fremstilling samt anvendelse af disse mærkede haptener ved immunoassays | |
DK176387A (da) | Fremgangsmaade til frembringelse af et funktionelt polypeptid i en eukaryot vaertscelle ved anvendelse af en rekombinant dna udtrykkelsesvektor omfattende en bk virusforstaerker | |
CY1105693T1 (el) | Συμπλοκα μεταφορας πρωτεϊνης ιικου πυρηνα-κατιοντικου λιπιδιου-νουκλεϊνικου οξεος | |
WO2000075352A3 (en) | Hcv/bvdv chimeric genomes and uses thereof | |
GB2363607A (en) | Method for selecting improved vectors | |
WO2001042297A3 (en) | Clasp-3 transmembrane protein | |
WO2002002142B1 (en) | Papillomavirus vaccine | |
Cloyd et al. | Generation serological assay for monitoring HIV exposure | |
DE50113411D1 (de) | Neue humane Androgenrezeptor-Varianten | |
ZA200105612B (en) | Use of the cell's own transport system for transferring nucleic acids across the nuclear membrane. |